DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease
NCT04218656
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
159
Enrollment
OTHER
Sponsor class
Conditions
Peripheral Artery Disease
Interventions
DRUG:
Rivaroxaban 2.5 Mg Oral Tablet
Sponsor
Radboud University Medical Center